Could a new drug combo tame pancreatic cancer and prevent clots?

NCT ID NCT07214298

Recruiting now Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding pegcetacoplan to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan targets part of the immune system to possibly slow tumor growth and reduce blood clots, a common complication. About 35 adults with advanced pancreatic cancer will participate. The goal is to see if the combination improves survival and reduces clot-related risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pegcetacoplan (a complement inhibitor) combined with mFOLFIRINOX chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil)
What this could lead to: If it works, this could lead to a more effective treatment for metastatic pancreatic cancer and help prevent dangerous blood clots.
What could go wrong: This is an early-phase trial with only 35 participants, so results may not apply to all patients. The combination may cause significant side effects, and the benefit is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA STAGE IV PANCREATIC CANCER AJCC V8

Contacts and locations

Locations

Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.